What role do incumbents like Ferring Pharmaceuticals play in driving technology innovations and growth in Women’s Health?
Women’s health has seen an immense increase in innovation from start-ups and entrepreneurs. But what are the traditional players doing? How can traditional big players help solve the most pressing challenges and address critical unmet needs in reproductive medicine and maternal health?
Hear from Ferring Pharmaceuticals who are at the forefront of women’s health, discussing what they’re doing to drive innovation, and their desire to invest, and partner with innovators in the women’s health.
Casper Johansen, Head of Scouting and Innovation Sourcing - Global Business Development, Ferring Pharmaceuticals
Driving growth, innovation and investment in Women’s Health & FemTech solutions
Discussing the dynamics in the European Women’s Health space, investment opportunities, deal flow and financial outcomes
- Looking at the deal flow gap compared to general healthcare, is the absence of investor support due to the lack of “sizeable exits”?
- What role do incumbents play in driving technology innovations in women’s health?
- Women’s Health solutions for gynaecology, fertility and maternity have garnered the largest funding, what about products that solve taboo topics (e.g., sexual health, menstrual health)? From an investor perspective what are the uncracked spaces? What are the crowded spaces?
- Is more commerciality from founders needed to drive growth in the space?
- Going to market in Europe- are there preferred enterprise routes? Is there a playbook?
Moderator: Karina Vazirova, Co-Founder & CEO, FemTech Lab
Jan Peutzfeldt, SVP Global Marketing and Global BD, Ferring Pharmaceuticals
Jess McCreadie, Principal, Octopus Ventures
Yahel Halamish, Principal, Nina Capital
Hans Gangeskar, CEO, Overture Life